Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A let-7 mimic is a synthetic double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous tumor suppressor microRNA, let-7. The let-7 family is one of the most well-studied microRNA groups and is frequently downregulated in various malignancies, including lung, ovarian, and breast cancers. By mimicking the natural let-7 microRNA, these synthetic agents bind to the 3' untranslated regions (UTRs) of specific oncogenic mRNAs, such as RAS, MYC, HMGA2, and Cyclin D1, leading to their degradation or translational repression. This restoration of let-7 activity aims to inhibit tumor cell proliferation, induce apoptosis, and overcome resistance to conventional therapies like platinum-based chemotherapy. Development of let-7 mimics as therapeutics often involves advanced delivery systems, such as lipid nanoparticles, to protect the RNA from nuclease degradation and facilitate targeted delivery to tumor tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on let-7 mimic.